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Abstract
Introduction
Self-reported  prediabetes  and  diabetes  rates  underes-
timate true prevalence, but mass laboratory screening is 
generally impractical for risk assessment and surveillance. 
We developed the Abnormal Glucose Risk Assessment-6 
(AGRA-6) tool to address this problem.
Methods
Self-report  data  were  obtained  from  the  1,887  adults 
(18 years or older) in the National Health and Nutrition 
Examination  Survey  (NHANES)  2005-2006  with  fasting 
plasma glucose and oral glucose tolerance tests. We created 
AGRA-6 models by using logistic regression. Performance 
was  validated  with  NHANES  2005-2006  data  by  using 
leave-1-out cross-validation. Standard performance char-
acteristics (sensitivity, specificity, predictive values, area 
under  receiver-operating  characteristic  curves)  were 
assessed, as was the potential efficiency of the models to 
reduce laboratory testing in screening efforts.
Results
Performance  was  good  for  all  models  under  testing 
conditions. Use of the AGRA-6 in screening efforts could 
reduce laboratory testing by at least 30% when sensitivity 
is maximized and at least 52% when sensitivity and speci-
ficity are balanced.
Conclusion
The AGRA-6 appears to be an effective, feasible tool that 
uses  self-reported  data  compatible  with  the  Behavioral 
Risk  Factor  Surveillance  System  to  assess  population-
level  prevalence,  identify  abnormal  glucose  levels,  opti-
mize screening efforts, and focus interventions to reduce 
the prevalence of abnormal glucose levels.
Introduction
Hyperglycemic  conditions  are  a  major  public  health 
problem, affecting an estimated 40% or more of the US 
adult population (1). Rates of hyperglycemic conditions, 
however, are not evenly distributed across the US popu-
lation; they vary by race, ethnicity, age, sex, and other 
social and place-based factors. Prevalence rates for com-
munities with different demographic characteristics vary 
(2).  Numerous  health  risks,  such  as  cardiovascular  dis-
ease, kidney failure, and vision loss, are associated with 
abnormal glucose levels (3). Substantial health risks are 
associated not only with levels high enough to be classi-
fied as diabetes but also with the intermediate zones of 
glucose intolerance, termed prediabetes (4-6). The health 
consequences of prediabetes and diabetes can be limited 
with exercise, diet, and medication (7), and such measures 
can  prevent  progression  from  prediabetes  to  diabetes 
(3). Cases of hyperglycemia should be identified so that 
interventions  can  be  focused  and  effective  health  plan-
ning provided, yet cases of abnormal glucose are difficult 
to identify through self-report. Nearly 90% of people who 
have prediabetes and 40% of those who have diabetes (1,8) 
are not aware of their clinical condition. These people may 
be asymptomatic yet vulnerable to complications (1), and 
may be less likely to undertake prevention efforts than 
those with a diagnosis (8,9).
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Although  all  levels  of  abnormal  glucose  have  health 
implications, the severity and scope of clinical outcomes 
vary  by  specific  subtypes  (10).  The  health  problems 
associated with overt diabetes, which affects almost 13% 
of the US population (1), include stroke, heart disease, 
kidney  and  eye  diseases  (3),  and  premature  death.  An 
estimated  30%  of  the  US  population  have  prediabetes; 
this population has a slightly higher risk for heart disease 
than do those who do not have prediabetes (4). They also 
have a significantly higher risk for developing diabetes 
(11,12). Prediabetes can be diagnosed from impaired fast-
ing  glucose  (IFG)  or  impaired  glucose  tolerance  (IGT), 
though these diagnoses carry somewhat different risks. 
Isolated IFG is associated with a slight increase in pre-
mature death compared with normal glucose tolerance, 
whereas IGT is not (3). However, IGT is more costly to 
treat than IFG (13) and carries a slightly higher risk for 
heart disease (4). People with both IFG and IGT appear 
to have the greatest risk of developing diabetes (12) and 
incur  the  greatest  costs  (13).  Because  of  differences  in 
clinical outcomes, some have suggested that distinct pre-
ventive recommendations should accompany the different 
types of prediabetes (4). 
Predictive algorithms provide a means to estimate rates 
of  abnormal  glucose  levels  (particularly  unrecognized 
abnormal  glucose  levels)  in  specific  populations  when 
laboratory data are not available, and they offer a method 
for determining individual risk that can be used to better 
focus screening efforts. A number of attempts have been 
made  to  quantify  abnormal  glucose  risk  by  using  such 
methods (3,14-20). These models have proved useful in 
both clinical practice and estimation of population illness 
(3,16,18) but have a  limitation: none provides a way to 
quantify  the  clinically  relevant  measures  of  abnormal 
glucose  that  may  be  important  in  health  surveillance 
and intervention. Most models focus on diabetes risk spe-
cifically (14,16,18,20), often using samples atypical of the 
general US population or requiring knowledge of clinical 
or  laboratoryoratory  data  (15,18-20).  This  makes  them 
impractical for surveillance and risk assessment for most 
measures of abnormal glucose in most US populations. A 
few recent models include a measure of both undiagnosed 
diabetes and prediabetes (14,15,17,19), but these do not 
distinguish between the types of prediabetes (14,17,19), 
consider specific populations (15), or focus exclusively on 
quantifying individual prediabetes risk for ease of use in 
clinical settings (17).
The purpose of this study was to improve on previous 
research by using a nationally representative sample of US 
adults to create a predictive algorithm for 6 of the clinically 
relevant measures of abnormal glucose (IFG, IGT, predia-
betes, IFG/IGT, undiagnosed diabetes, and total abnormal 
glucose) by using readily availaboratoryle self-report data. 
To maximize the usefulness of this instrument for public 
health work, we employed variables availaboratoryle from 
the Behavioral Risk Factor Surveillance System (BRFSS), 
administered yearly by US states and territories.
Methods
Data source
This  study  used  the  public  dataset  from  the  nation-
ally  representative  National  Health  and  Nutrition 
Examination  Survey  (NHANES)  2005-2006  (21),  which 
oversampled minority populations. Households were ran-
domly  assigned  to  morning  or  evening  examination. 
Morning examination included a fasting plasma glucose 
test  (FPG)  and  an  oral  glucose  tolerance  test  (OGTT); 
1,887 participants aged 18 years or older had valid mea-
sures for both FPG and OGTT. More detailed methods of 
the NHANES 2005-2006 (21) and the laboratory tests can 
be found elsewhere (22).
The Abnormal Glucose Risk Assessment-6 models
We developed 6 models to estimate all clinically relevant 
measures  of  abnormal  glucose.  Model  1  estimates  IFG. 
Model  2  estimates  IGT.  Model  3  estimates  prediabetes 
(either  IFG  or  IGT).  Model  4  estimates  what  we  term 
“high-risk  prediabetes”  (both  IFG  and  IGT).  Model  5 
estimates undiagnosed diabetes. Model 6 estimates total 
abnormal  glucose,  which  includes  prediabetes,  undiag-
nosed diabetes, and diagnosed diabetes.
Study samples
For the first 4 models — all estimates of prediabetes risk 
— we excluded the 308 people who met the criteria for 
frank diabetes, whether they were aware (201) or unaware 
(107) of this diagnosis. This left 1,579 people (of the 1,887) 
for estimates for models 1 through 4. For model 5, estimat-
ing undiagnosed diabetes, we excluded people who were 
aware they had diabetes (201), yielding a sample of 1,686 
people. For the model estimating total abnormal glucose VOLUME 7: NO. 2
MARCH 2010
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burden (model 6), we included all 1,887 adults with FPG 
and OGTT scores.
Abnormal glucose variables
Operational  definitions  of  IFG,  IGT,  prediabetes,  and 
diabetes were developed on the basis of current diagnos-
tic  criteria  of  the  American  Diabetes  Association  (23). 
IFG was defined by an elevated FPG concentration (≥100 
and <126 mg/dL). IGT was defined by an elevated 2-hour 
plasma glucose concentration (≥140 and <200 mg/dL) after 
a 75-g glucose load on the OGTT. Prediabetes was defined 
as having either IFG or IGT. High-risk prediabetes was 
defined as having both IFG and IGT; the definition was 
based on previous work about the increased risk of this 
situation (4,12,13). Diabetes was defined as having a fast-
ing plasma glucose of 126 mg/dL or more or a 2-hour plas-
ma glucose above 200 mg/dL. Total abnormal glucose was 
defined as having prediabetes of any form, undiagnosed 
diabetes, or diagnosed diabetes. Diagnosed diabetes was 
determined by individual self-report and did not include 
gestational diabetes, which was not assessed in the 2005-
2006 NHANES.
Predictor variables
On  the  basis  of  a  literature  review,  we  identified  11 
self-reported  predictor  variables  that  were  available  in 
the NHANES and BRFSS and were known to be asso-
ciated  with  diabetes  risk  for  possible  inclusion  in  each 
Abnormal  Glucose  Risk  Assessment-6  (AGRA-6)  model. 
Demographic variables included age (continuous 18-85 y), 
sex, self-reported race/ethnicity, and educational attain-
ment. Behavioral variables included smoking status and 
participating in any leisure-time physical activities. Health 
condition variables included body mass index (BMI) (con-
tinuous and truncated from ≤10 to ≥100 to avoid outliers), 
history of hypertension, use of hypertension medication, 
high cholesterol, and family history of diabetes.
Statistical analysis
From these possible variables, we derived optimal logis-
tic  prediction  models  by  using  the  Akaike  information 
criterion  (AIC),  which  selects  a  model  that  maximizes 
predictive power while minimizing the number of predic-
tive variables (24). For each of the 6 outcome variables, 
a  unique,  optimal  predictive  model  was  built  from  the 
set of potential predictive variables. The main statistical   
analyses  were  performed  with  SAS  version  9.1  (SAS 
Institute, Inc, Cary, North Carolina). Multiple imputations 
were performed with SRCware version 1.0 (University of 
Michigan, Ann Arbor, Michigan). All of the models took 
into account the complex survey design.
Model validation and performance
We validated the final models with the leave-1-out cross-
validation (LOOCV) method. The LOOCV uses a single 
observation from the whole sample as the validation data, 
and the remaining observations as the training data. This 
process is repeated until each observation in the entire 
sample is used once as the validation data. The sensitiv-
ity, specificity, and positive and negative predictive values 
were obtained for all 6 models under LOOCV testing con-
ditions. The area under receiver-operating characteristic 
curves (AUC) provides a single value that indicates the 
discrimination of the model (ie, its ability to identify true 
risk)  at  all  possible  values  that  could  be  chosen  as  cut 
points to distinguish risk from nonrisk.
In  practical  applications,  however,  specific  cut  points 
must be chosen to distinguish risk from nonrisk. Whether 
that cut point should prioritize identifying true positives, 
true negatives, or some balance between the 2 depends on 
the objective of the analysis and the budget of the program 
doing the analysis. For instance, when algorithms are used 
for screening purposes, it would generally be more desir-
able to find all cases of prediabetes, at the cost of some 
false positives. In this situation, the cut point delineating 
risk  from  nonrisk  should  be  set  to  maximize  sensitiv-
ity (finding all true positives) over specificity (identifying 
only true negatives). A positive finding of risk would then 
be followed by a laboratory test. For surveillance, on the 
other hand, the goal would typically be to strike a balance 
between  types  of  error  (false  positives  and  false  nega-
tives). A higher specificity cut point is generally more cost- 
effective unless clinical priorities dominate (such as use of 
higher sensitivity cut points to find gestational diabetes).
Therefore, to maximize the usefulness of the AGRA-6, 
we present the predictive characteristics of each AGRA-6 
model for 2 thresholds: 1) the high-sensitivity threshold, 
where a cut point is selected so that sensitivity is reached 
to  about  0.9  (approximately  90%  of  positive  cases  will 
be  correctly  identified),  and  2)  the  balanced-sensitivity/
specificity threshold, where a cut point is selected so that 
sensitivity and specificity are equal. This will enable users VOLUME 7: NO. 2
MARCH 2010
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of the tool to determine optimal cut points on the basis of 
local or programmatic needs and resources.
Results
Descriptive statistics for this nationally representative 
sample  of  adults  aged  18  or  older  are  summarized  for 
each of the possible predictor variables and for all 6 of the 
abnormal glucose outcome variables (Table 1).
The  final  AGRA-6  models  (Table  2)  show  that  the 
number  of  the  11  possible  predictor  variables  differed 
by  outcome  variable.  For  instance,  the  optimal  model 
for high-risk prediabetes included only 4 of the possible 
predictor variables, whereas the optimal model for total 
abnormal glucose included 7 variables. In no final model 
were both hypertension and use of hypertension medica-
tion included together.
We  examined  the  performance  and  efficiency  of  each 
model at both the high sensitivity and balanced sensitiv-
ity  and  specificity  cut  points  (Table  3).  All  models  had 
AUC values within the acceptable range (0.72-0.80), and 
most were higher than 0.75. Under the high sensitivity 
threshold, the 2 models (IFG and prediabetes) that would 
deem the most people to be high risk would still predict 
30% of the total population to be no-risk and would not 
require  testing  from  them.  The  high  sensitivity  model 
for undiagnosed diabetes would predict only 34% of the 
population at high risk and would avert testing for 66% 
of the population. If model 6 was used as the first step in 
a 2-stage screening for total abnormal glucose prevalence 
in a population under this cut point, it would capture 90% 
of true positives while keeping 33% of the population from 
laboratory testing.
Under the balanced sensitivity and specificity threshold, 
all models had sensitivity values from 0.64 to 0.77 and 
specificity values from 0.67 to 0.73. If the AGRA-6 models 
were used with survey data such as BRFSS data to esti-
mate abnormal glucose prevalence in a region, the AGRA 
would be able to accurately predict about 70% of various 
clinical classifications of both total abnormal glucose cases 
(sensitivity)  and  noncases  (specificity)  in  that  region.  If 
model 6 was used to predict the total abnormal glucose 
prevalence in a population under this cut point, it would 
misclassify 27% of true negatives. Model 6 would keep 52% 
of the population from laboratory testing.
Discussion
The AGRA-6 is the first risk assessment tool to estimate 
6  clinically  meaningful  measures  of  abnormal  glucose 
including 4 distinct categories of prediabetes, undiagnosed 
diabetes,  and  total  abnormal  glucose  prevalence.  It  is 
designed to be used with readily available self-reported 
data, particularly BRFSS data. The AGRA-6 offers these 
advantages while maintaining comparable performance to 
existing measures that include fewer outcome variables 
and/or necessitate clinical or laboratory data.
The AGRA-6 should prove helpful in efforts to achieve 
at least 3 public health goals. First, it could be useful 
for surveillance. AGRA-6 estimates have their own uses 
and  can  be  coupled  with  geographic  data  to  highlight 
neighborhoods and other localities where the prevalence 
of abnormal glucose is disproportionate. Health planners 
and advocates can also use these models to compare, for 
the first time, the prevalence of different types of predia-
betes in their communities and, thus, different types of 
clinical  risk.  Current  prediabetes  prevalence  estimates 
based on the BRFSS self-report of being diagnosed with 
prediabetes may miss nearly 90% of prediabetes cases. 
Second, the AGRA-6 could be useful for screening. One 
key implication of our study is that readily available data 
from various community and public health settings could 
be used to enhance the efficiency of mass screening to 
enable focused screening for prediabetes and previously 
undiagnosed diabetes. All of the models would reduce the 
need for testing to find true positives. Finally, the AGRA-
6 can be useful for individual risk assessment. In clinical 
practice, the models could be incorporated into electronic 
medical records to produce risk estimates for individual 
patients for all of the 6 abnormal glucose levels. For the 
general public, the AGRA-6 is being developed into an 
online tool that can provide individual risk assessment 
for  all  6  levels  of  abnormal  glucose  (www.caldiabetes.
org).
The AGRA-6 provides 4 key advantages over previous 
work in this area. First, it predicts 6 of the clinically mean-
ingful levels of abnormal glucose, whereas previous work 
has included only some of these outcomes. Second, it uses 
basic self-report data to generate predictions on the basis 
of actual laboratory findings. It does not require labora-
tory work or additional clinical information. Third, it is 
directly compatible with the BRFSS, providing a link to 
existing surveillance efforts in many locations. Fourth, it VOLUME 7: NO. 2
MARCH 2010
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is based on a representative sample of the entire US adult 
population.
Limitations
The AGRA-6 has some limitations. Computing devices 
— either personal computers or personal digital assistants 
— will generally be required to calculate risk models. This 
should  not  present  a  barrier  for  most  AGRA-6  applica-
tions, but when these devices are unavailable or impracti-
cal, other tools (14,17,18) may be preferable even if they do 
not allow for the measure of as many subtypes of abnormal 
glucose risk.
Second,  the  AGRA-6  models  have  been  validated  by 
using data from the sample on which they were created, 
which may result in more overestimations of model per-
formance than would be observed if the algorithms were 
tested in other data sets. We did this because there are 
no other comparable nationally representative data sets 
that contain laboratory tests for both FPG and OGTT. To 
minimize the impact of this approach, we used the LOOCV 
method, which is a method often used for creating testing 
data sets from training data sets (25).
Third,  although  these  models  were  generated  from  a 
nationally  representative  US  sample,  they  may  not  be 
appropriate  for  all  US  subpopulations  and  geographic 
areas or for many international populations (26). The per-
formance of the AGRA-6 models may also vary by demo-
graphic subgroups (younger vs older, heavier vs lighter, 
different racial/ethnic groups), and a consideration of this 
variation for the AGRA-6 models and for other commonly 
used predictive models is an area for further study. Some 
of  the  predictive  variables  rely  on  prior  access  to  care, 
including  having  a  diagnosis  of  hypertension  or  high 
cholesterol  and  taking  hypertension  medication.  Actual 
prevalence in people who lack access to care may thus be 
underestimated. Also, the available sample was not large 
enough to allow us to include Asians/Pacific Islanders as 
distinct subpopulations, leaving open a question regarding 
its usefulness for classifying risk in these groups.
Fourth, the AGRA-6 shares the limitations of any pre-
dictive model in that some people will be misclassified. 
Whether  people  are  misclassified  as  false  positives  or 
false  negatives  can  be  manipulated  to  some  degree  by 
the chosen threshold levels used to delineate risk. In all 
public  health  surveillance  and  screening,  there  will  be 
tradeoffs  between  precision  and  cost,  and  no  option  is 
infallible. The problems associated with misclassification 
must be weighed against the specific goals and budget of 
the program.
Implications for public health practice
The  health  risks  of  type  2  diabetes  can  be  mitigated 
through individual, community-based, and even structural 
and  policy  interventions  (3).  Lifestyle  interventions  can 
also prevent or delay the onset of type 2 diabetes among 
high-risk people, such as those with prediabetes (6). One 
major task for public health agencies and programs is to 
identify groups and individuals who would benefit from 
these  interventions.  The  AGRA-6  allows  public  health 
organizations to identify populations and individuals who 
would probably benefit from these interventions and to 
facilitate  cost-effective  screening  of  these  populations. 
This could further facilitate the allocation of public health 
resources for focused interventions to reduce the illness 
and death risks of prediabetes and diabetes in the United 
States. The AGRA-6 models should also prove useful for 
county, state, and national surveillance efforts to assess 
the progression of this epidemic.
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Demographic 
Characteristics Mean (95% CI) Unweighted n
Age, y  4.7 (44.9-4.) 1,887
BMI (kg/m2) 28. (28.0-28.7) 1,81a
  Percentage (95 % CI) Unweighted nb
Female 2.0 (49.2-4.8) 892
Race/ethnicity
Non-Hispanic white 71.2 (9.0-7.4) 904
Non-Hispanic black 11.4 (10.2-12.) 42
Hispanic 12.0 (10.-1.4) 4
Other .4 (4.1-.7) 7
Education
Less than high school gradu-
ate
1. (14.8-18.) 44
High school graduate 2.1 (2.-28.) 42
Some college 7. (4.-0.1) 819
Smoking status
Current 24. (21.9-27.0) 2
Former 2.4 (22.9-27.9) 48
Never 0.1 (47.-.0) 8
No leisure-time physical 
activity
2.7 (21.4-2.1) 49
  % (95 % CI) Unweighted nb
Health conditions
Told at risk for diabetes 1.2 (1.0-17.) 240
Medical history of CVD 10.7 (9.0-12.) 22
Hypertension 0. (27.8-2.8) 21
Take medication for hyper-
tension
24. (22.2-2.8) 18
High cholesterol 41.2 (7.9-44.) 18
Diabetes in family 42.1 (9.2-4.0) 74
Abnormal glucose status
Impaired fasting glucose 
(IFG)
2.4 (21.1-2.7) 44
Impaired glucose tolerance 
(IGT)
1.4 (11.-1.) 22
Prediabetes (IFG or IGT) 29.0 (2.-1.) 8
High risk for prediabetes 
(IFG and IGT)
7.8 (.4-9.) 10
Undiagnosed diabetes .0 (.8-.1) 10
Total abnormal glucosec 41.4 (8.7-44.2) 8
 
Abbreviations: NHANES, National Health and Nutrition Examination Survey; 
CI, confidence interval; BMI, body mass index; CVD, cardiovascular disease. 
a Subjects were removed as outliers if BMI was ≤10 or ≥100. 
b Totals vary due to missing data. 
cIncludes prediabetes, undiagnosed diabetes, and diagnosed diabetes.
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Table 2. AGRA-6 Modelsa for Predicting Abnormal Glucose Levels by Self-Reported Data
Model Predictive Equationb
Model 1: Impaired fasting glucose (IFG) Log (odds of IFG) = -4.189 + (0.0 × [age]) + (0.0419 × [BMI]) + (1.008 × [male]) –(0.40 × [NH 
white]) + (0.07 × [NH black]) – (0.87 × [MX American]) + (0.77 × [HTN meds])
Mode 2: Impaired glucose tolerance (IGT) Log (odds of IGT) = -4.98 + (0.0422 × [age]) + (0.029 × [BMI]) + (0.498 × [hypertension]) – (0.94 
× [physical activity]) + (0.449 × [high cholesterol])
Model : Prediabetes (PDM) Log (odds of PDM) = -4.128 + (0.0444 × [age]) + (0.0408 × [BMI]) + (0.8448 × [male]) –  (0.4041 × [NH 
White]) + (0.1888 × [NH Black]) – (0.448 × [MX American]) + (0.8 × [hypertension])
Model 4: High-risk prediabetes (HRP) Log (odds of HRP) = -.408 + (0.041 × [age]) + (0.094 × [BMI]) + (0.8947 × [hypertension]) + 
(0.428 × [high cholesterol])
Model : Undiagnosed diabetes (UDM) Log (odds of UDM) = -7.91 + (0.04 × [age]) + (0.082 × [BMI]) + (0.9804 × [hypertension]) + 
(0.272 × [less HS grad]) + (0.88 × [HS grad])
Model : Total abnormal glucose (TAG) Log (odds of TAG) = -4.4298 + (0.048 × [age]) + (0.049 × [BMI]) + (0.718 × [male]) – (0.40 × [NH 
white]) + (0.1420 × [NH black]) –  (0.497 × [MX American]) + (0.704 × [hypertension]) + (0.1981 × 
[high cholesterol]) + (0.411 × [less HS grad]) + (0.0910 × [HS grad])
 
Abbreviations: AGRA, Abnormal Glucose Risk Assessment; BMI, body mass index; NH, non-Hispanic; MX, Mexican; HTN meds, hypertension medications; HS 
grad, high school graduate. 
a The coefficients in the equations are derived from the optimal logistic prediction models using the Akaike information criterion. 
b The log (odds of event) is defined as log [P/(1-P)], where P is the probability of an event. Substitute categorical terms with 1 if yes and 0 if otherwise.
Table 3. Performance of AGRA-6 Predictive Models at 2 Possible Thresholds: High Sensitivitya and Balanced Sensitivity and 
Specificityb 
Conditions Model 1, IFG Model 2, IGT Model 3, PDM Model 4, HRP Model 5, UDM Model 6, TAG
Area under the ROC curve 0.72 0.78 0.7 0.78 0.80 0.80
High sensitivity threshold
Cut point 0.1 0.10 0.20 0.0 0.0 0.2
Sensitivity 0.89 0.8 0.89 0.90 0.77 0.90
Specificity 0.40 0. 0.40 0. 0.9 0.47
Positive predictive value 0. 0.2 0.4 0.18 0.1 0.9
Negative predictive value 0.90 0.9 0.87 0.98 0.98 0.8
Proportion who would screen at high 
riskc
70  4  70 49 4 7
Proportion of laboratory tests 
avoided
0 4 0 1   
 
Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance; PDM, prediabetes; HRP, high-risk prediabetes; UDM, undiagnosed diabetes; TAG, 
total abnormal glucose; ROC, receiver-operating characteristic. 
a Finding true positives is prioritized. 
b Finding true positives is balanced with finding true negatives. 
c Identifies the percentage of those tested who would have a model-predicted risk score that is greater than or equal to the cut point. In a screening situation, 
this would be the percentage of people who would be recommended for further testing.
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Conditions Model 1, IFG Model 2, IGT Model 3, PDM Model 4, HRP Model 5, UDM Model 6, TAG
Balanced sensitivity and specificity threshold
Cut point 0.0 0.1 0. 0.10 0.0 0.40
Sensitivity 0.4 0.74 0.9 0.71 0.77 0.7
Specificity 0.8 0.8 0.7 0.7 0.70 0.7
Positive predictive value 0.44 0.2 0. 0.21 0.1 0.9
Negative predictive value 0.8 0.9 0.80 0.9 0.98 0.7
Proportion who would screen at 
high risk
41 9 4 1 4 48
Proportion of laboratory tests 
avoided
9 1 4 9  2
 
Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance; PDM, prediabetes; HRP, high-risk prediabetes; UDM, undiagnosed diabetes; TAG, 
total abnormal glucose; ROC, receiver-operating characteristic. 
a Finding true positives is prioritized. 
b Finding true positives is balanced with finding true negatives. 
c Identifies the percentage of those tested who would have a model-predicted risk score that is greater than or equal to the cut point. In a screening situation, 
this would be the percentage of people who would be recommended for further testing.
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